Increased blood COASY DNA methylation levels a potential biomarker for early pathology of Alzheimer’s disease

DOI PDF Web Site 2 Citations 24 References Open Access

Description

<jats:title>Abstract</jats:title><jats:p>Early diagnosis of dementia including Alzheimer’s disease (AD) is an urgent medical and welfare issue. However, to date, no simple biometrics have been available. We reported that blood DNA methylation levels of the <jats:italic>COASY</jats:italic> gene, which encodes coenzyme A synthase, were increased in individuals with AD and amnestic mild cognitive impairment (aMCI). The present study sought to replicate these findings with larger numbers of samples. Another objective was to clarify whether <jats:italic>COASY</jats:italic> methylation is associated with neurodegeneration through a comparison of AD, AD with cardiovascular disease (CVD), and vascular dementia (VaD). We measured blood <jats:italic>COASY</jats:italic> methylation levels in normal controls (NCs) (<jats:italic>n</jats:italic> = 200), and individuals with aMCI (<jats:italic>n</jats:italic> = 22), AD (<jats:italic>n</jats:italic> = 151), and VaD (<jats:italic>n</jats:italic> = 21). Compared with NCs, they were significantly higher in individuals with aMCI and AD. Further, they were significantly higher in AD patients without cardiovascular diseases compared to AD patients with them. These findings suggest that <jats:italic>COASY</jats:italic> methylation levels may be related to neurodegeneration in AD.</jats:p>

Journal

  • Scientific Reports

    Scientific Reports 10 (1), 12217-, 2020-07-22

    Springer Science and Business Media LLC

Citations (2)*help

See more

References(24)*help

See more

Related Projects

See more

Report a problem

Back to top